Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold my shares @ .65 today ... I'll admit it was a mistake but at least I made a quick 20% gain which I'll take ... congrats to others here!
FVRG - damn up 42%! ... despite my gain, might have blown it by swing trading without any core shares. Of course, this one is volatile so there might still be another chance... I'm not going to chase.
HHSE - nothing about the VODWIZ partner videos announced yet.
I'm still optimistic as, other than backruptcy, the shares are undervalued and I like that VODWIZ is functional ... if ANY of the major expected catalysts would work out (just ONCE!) then HHSE will do VERY well ... common Eric, let's see an annoucment about the VODWIZ partners soon (as was indicated) or at least let us know what's reason for the holdup!
FVRG - sold too soon ... looks to be running on some higher volume.
FVRG - sold for 22% gain... looking to get back in.
NBY - Sold @ 1.66 - I'm into swing-trading these days so will look to get in lower (as seems to usually happen these days following good news).
NBY - should have pulled the trigger ... now up 15%.
I bought @ .22 and sold @ .39 so that was a pretty nice and quick gain! Owe you one! (Or two, or three...)
Just noticed she reached .65 ... congrats!
NBY - up only 5% despite very good phase II results ... might have to purchase some more ... especially if it creeps below Friday's close!
http://ih.advfn.com/p.php?pid=nmona&article=59222570&symbol=NBY
ACBC - I'm swing trading and looking to get back in... I should probably hold but understanding this one is way above my experience level!
You know better than that! Youtube requires a much faster connection and doesn't have full movies in 4k!
So the original point holds there is some really good synergy between Nuvola and VODWIZ.
They are working on 4K content for the VODWIZ to stream to the NP-1... not sure if you read the PR:
http://finance.yahoo.com/news/nanotech-entertainment-ntek-expands-operations-140200997.html
"The move enables NanoTech to keep pace with its expanding video library and storage demands as it builds out its 4K UltraHD Video library. "
It looks like they have started with "Turtle"... did you see David's tweets?
Or is it your belief that NTEK won't be streaming content as indicated? If so, I'm confused about your mixed enthusiasm?
"If they advertise the Nuvola NP properly, they could have a winner here. "
Don't forget that would have spillover/synergy into the VODWIZ portal too! Should be a nice recurring revenue stream over time, right?
OK - we get that you believe in the effficient market hypothesis ... market activity is the best indicator of company value.
However, if you believe in the efficient market hypothesis, then EVERY company is correctly valued to reflect available information. If so, why don't you buy a mutual fund rather than worry about any specific companies?
Or do you not believe in the efficient market hypothesis, in which case all your reference to buy and sell orders is meaningless.
My guess is that you were not at a HARPS or Walmart ... a bit unrealisitic to expect HHSE to negotiate all the local chain stores when they are a national distributor.
Take a look the INO chart ... it also had a huge temporary high-volume spike prior to the partnership being announced, which was unexplainable at the time. You could correct that the ADXS spike is technical traders, but I don't think it's certain.
Either way, if we drop below 5.80, especially if the volume on the drop is lower than the volume on the increase, I'll be looking to re-aquire my trading shares... nonetheless, I'm not going to bet too much on ADXS as too many questions.
NTEK - "NanoTech Entertainment (NTEK) Ships Nuvola NP-H1 4K Ultra High Definition (4K UltraHD) Set Top Computer"
http://finance.yahoo.com/news/nanotech-entertainment-ntek-ships-nuvola-130000712.html
I'll be very excited to see the 4K streaming independently demonstrated on youtube etc ... if the tech works, that bodes very well for HHSE as -- regardless of the potential -- legitimacy of NTEK means legitimacy of VODWIZ.
FVRG - took a very small starter yesterday... based entirely on the financials ... like the revenues and growth relative to enterprise value.
Filing says to expect some financing but that it is anticipated to be debt, so we'll see...
http://ih.advfn.com/p.php?pid=nmona&article=59183294&symbol=FVRG
ForeverGreen Achieves Key Financial Metrics
PrintAlert
Forevergreen Worldwi (OTCBB:FVRG)
Intraday Stock Chart
Today : Thursday 12 September 2013
ForeverGreen Worldwide Corporation (FVRG), a leading provider of nutritional foods and other healthy products, today announced that several important financial measurements have recently turned positive for the company.
Recent highlights included:
Positive EBITDA – positive EBITDA during Q2
Positive non-GAAP earnings
Operating Profitability – net cash provided by operating activities of approximately 1½ cents/share during Q2 2013, continues to escalate in Q3 2013
Revenue increasing – Q3 2013 will be significantly higher than Q3 2012 revenues with higher gross margins.
“We have two major factors that are driving our growth and profitability beyond any prior historical levels. First, we have a Class I FDA listed medical device to market, and secondly we are selling in 136 countries. This number has increased by 119 new countries since the beginning of 2013. Our number of active distributors for just the FG Xpress product is over 13,000, and we are now adding nearly 2,500 new distributors each month. We look forward to continuing to deliver the important metrics our shareholders desire,” commented Ron Williams, CEO.
ForeverGreen Worldwide Corporation develops, manufactures and distributes an expansive line of all natural whole foods and products to North America, Australia, Europe, Asia, South America and Africa. Offerings include their new global offering, Power Strips. Additionally, they offer Azul and FrequenSea™ whole-food beverages with industry exclusive Marine Phytoplankton, Versativa line of hemp-based whole-food products, A.I.M. Transfer Factor immune support, 03World™ weight management products, Pulse-8 powdered L-arginine formula, TRUessence™ Essential Oils and Apothecary, 24Karat Chocolate®, and an entire catalog of meals, snacks, household cleaners and personal care products. www.forevergreen.org
I bought some yesterday @ .52 ... might have got lucky ahead of the news today!
I'll be upfront that I've always been a bit skeptical about the application of TA, but at the same time I'm open to learning more.
In this regard, I'm very curious at what point if any over -- say the last 4 months -- were the techinicals most bullish for INO? When was it considered most "safe" to 'go long' and according to which specific indicator(s)?
Wow, that's quite optimisitic! Of course, CEO's tend to be biased about these things but, that said, there seems to be quite good revenue growth relative to the approx $13M enterprise value ... I've just started looking and will keep digging.
I appreciate the research!
I followed you over here! Based on recent sales growth, has anyone done any analysis of expected revenues and earnings for 2014?
"NanoTech Triples its Network Operations Equipment with over 50,000 Hours of Video Storage "
http://finance.yahoo.com/news/nanotech-entertainment-ntek-expands-operations-140200997.html
Expansion to accomodate VODWIZ?
ADXS +50% - Despite our questions and hesitations, still nice to see. I sold 1/2 before today's run, but glad I averaged down and still have a decent position of shares.
I'm thinking this is driven by the INO deal yesterday...now ADXS is the sole option.
Also, keep in mind INO ran BEFORE the partnership was officially announced (althought the CEO had been saying they were working on a partnership), so perhaps the same might be happening here.
Understood .... thanks!
I see how what you are saying would explain the share price drop ... I promise one last question!!
Do you think any/all of those issues would reduce appeal of an agreement from the perspective of potential partners?
Keep in mind that the shareprice/share-structure in-and-of-itself would be irrelevant as to the benefits of liscensing the tech.
If partners could potentially circumvent trust issues by way of contactual terms of terms and conditions, then perhaps there is still good potential given the much lower share price. If however, these recent issues not only harm shareholders and financial health the company but also serve to harm the perception of parterns then the reduced shareprice would not be sufficient to offset what is not only a worse financial condition ... perhaps the partners will be looking at everything that has transpired and think that something to them smells fishy that they might have less trust in the science, which is already by nature questionable.
Either way, I'm glad to have sold much of my shares yesterday ... made a little back on some shares I had averaged down.
Thanks for your patience ... I'm raising these questions not becuase I disagree with anything you've said but to better-understand and learn.
MIN.V/EXMGF ... positive metallurgy results released today. I just purchased more a couple of days ago so perhaps I'll have some luck and a little run tomorrow.
http://excelsiormining.com/index.php/news/news-2013/413-excelsior-advances-prefeasibility-provides-positive-metallurgy-test-results-at-gunnison
Looks pretty bullish..
1. Metallurgy is an important aspect of the feasibility study. (Incidentally, if Ucore gets a favorable report, I'll likely load the boat).
2. Royalty financing is in place.
3. The pre-feasibility study was extremely favorable that there is room for error ... yet the metallurgy results seem superior to initial estimates.
4. The main issue is probably permitting but in that regard the location seems ideal.
Any eyes on this one appreciated.
Thanks Malc ... I just read the filing (in the car) and found out more convertible debt was issued today ... allowing up to 5% of the company shares to be owned for just $700-$800K (to my memory).
I really wish I had more time to get into this (and PLSB, and IRE, and SAN) but its been extremely busy. Do you know offhand what amount of dollars and total shares would be issued (potentially) by this year's convertible debt thus far?
What is incredibly odd to me is that I see 2 scenarios:
1. The science is not favorable. But then how could the results look so good? Are clinical trials unreliable? (I understand that many trials that pass phase II fail phase III but I understand one of the main issues is that phase II trials tend not to be randomized, poor test design and also that shorter-term indicators are measured rather than the actual positive outcomes attributed to the treatment ... in this case those do not seem to be huge issues as the baseline and outcomes seem to be pretty much well-established and there is high statistical significance.)
2. The science is favorable. If so, even with poor management, wouldn't the potential earnings be soooo great that something favorable could be negotiated for all parties. I agree Moore is greedy but I don't think he's stupid... why can't a partner be established? ... if suitors are afraid of the CEO, why not negotiate some clauses about executive compensation, put on a board member, and/or establish necessary and conditional milestones etc (like INO/Roche). There is much more to gain from this technology versus diluting shareholders so I'm really dumbfounded what's going on.
For me, I still hold to the science, and believe that management, however greedy, should be able to form a parternship ... the potential is to great to be otherwise. However, if the science is poor or the market is not efficient to develop the science, then it might not make sense to invest in this space as it's just too unprecdictable...
I don't well-understood the main fundmanental reasons it dropped in the first place ... so I don't know.
My intuition is that it was way oversold as nothing (to my knowledge) really changed with respect to the science... I thought statistically signficant clinical trials are generally trustworthy but I don't have the experience to really know... perhaps my original concern about lack of control group for the India trial was valid?
Sold some ADXS @ 6.78.
Even better today! Guess someone is very impressed with the science ... (lol).
Must be some INO sympathy ... with the Roche partnership ADXS now the 'only game in town'.
Bought back my INO shares I sold for 2.44 a few days ago at 2.38 .. can't believe cheaper now than then!
Amazing that more of a run BEFORE the news ... must have leaked. Game is rigged!
INO/ROCHE Partnership!!
http://www.digitaljournal.com/pr/1457624
http://ih.advfn.com/p.php?pid=nmona&article=59139492&symbol=INO
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products
PR Newswire
BASEL, Switzerland and BLUE BELL, Pa., Sept. 10, 2013
BASEL, Switzerland and BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.
Roche acquired an exclusive license for Inovio's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of Inovio's CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional vaccine opportunities in connection with a collaborative research program in oncology. Roche and Inovio will collaborate to further develop INO-5150 and INO-1800.
Under the terms of the agreement, Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800. In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.
Commenting on the deal, Hy Levitsky, Head of Cancer Immunology Experimental Medicine at Roche, said: "At Roche we are always interested in finding first-in-class and best-in-class therapies that may become the next generation treatments for patients with different types of cancer. INO-5150 will allow promising combination opportunities with the Roche portfolio, particularly with our emerging cancer immunotherapy molecules." Janet Hammond, Head of Infectious Diseases Discovery & Translational Area at Roche, added: "We are very excited to have this potentially very important and novel mechanism of action as part of our portfolio as we seek to address the significant unmet medical need in chronic hepatitis B infection."
"This partnership represents an important milestone in Inovio's growth and maturing product portfolio. Roche brings to our immunotherapy candidates its leadership position and track record for developing and marketing innovative first-in-class therapies," said Dr. J. Joseph Kim, Inovio's President and CEO. "Collaborating with the world's preeminent oncology development partner allows us to rapidly advance two of our promising near-clinical stage immunotherapy products from our product pipeline as we continue development of our phase II lead product, VGX-3100, for treatment of HPV-related cancers and dysplasia."
About INO-5150 for Prostate Cancer
Inovio's dual-antigen synthetic DNA vaccine (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA). A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that were the highest generated by a PSA-based immunotherapy in animal studies and were similar to the immune responses generated by VGX-3100, Inovio's phase II-stage therapeutic HPV vaccine that generated best-in-class T-cell responses in a phase I study.
Inovio's SynCon® DNA vaccine for prostate cancer was designed with PSA and PSMA synthetic consensus immunogens based on human and macaque sequences, resulting in amino acid sequences that differ slightly from the native human protein. In humans, this novel approach is utilized to help the body's immune system recognize cancerous cells created in the body as 'foreign', overcoming the body's self-tolerance of these cells and mounting an immune response to clear them.
About INO-1800 for Hepatitis B
Inovio has reported preclinical data showing its hepatitis B vaccine (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate this DNA vaccine's potential to treat hepatitis B infection and prevent further development of the infection into liver cancer in humans.
In a preclinical study, researchers found the vaccine-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells.
To provide worldwide rights to Roche, Inovio has re-acquired its hepatitis B, Asian-country rights from Inovio's international affiliate.
Disease Background
Prostate Cancer
Prostate cancer is the second most frequently diagnosed cancer of men. Nearly three-quarters of the registered cases occur in developed countries. Accounting for nearly 300,000 deaths each year, prostate cancer is the sixth leading cause of death from cancer in men. The development of a new treatment for prostate cancer would be a significant medical advancement given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and are often not a long-term cure.
Hepatitis B and Liver Cancer
Hepatitis B is a disease characterized by inflammation of the liver. The virus is extremely infectious – 100 times more so than HIV – and 400 million people are chronically infected worldwide. Hepatitis B contributes to an estimated 1 million deaths worldwide each year.
Liver cancer is the third most common cancer and the most deadly, killing most patients within five years of diagnosis. About 600,000 new cases arise each year. One of the major causes and risk factors for liver cancer is infection by hepatitis B.
Read more: http://www.digitaljournal.com/pr/1457624#ixzz2eUeMsKfU
LLEN - now that no XIN, my only China play... results look REALLY good so let's see what happens tomorrow.
http://ih.advfn.com/p.php?pid=nmona&article=59136143&symbol=LLEN
First Quarter Continuing Operations Highlights
Coal production up 54% y/y to 228,000 tons
Revenue up 29% y/y to $51.2 million from 39.4 million
Gross profit up 92.5% y/y to $19.1 million from 9.9 million
Net income attributable to L&L shareholders up 133% y/y to $10.7 million from 4.6 million
Diluted earnings per share up 108% y/y to $0.27 from $0.13.
"The first quarter of fiscal 2014 was one of progress and growth for L&L," stated Clayton Fong, Vice President of US Operations for L&L Energy. "Coal production increased significantly, revenue grew impressively, and we improved profitability as we rework our mix of business toward more profitable segments. Our balance sheet remains strong. We will further enhance our ability to fund growth with our upcoming Taiwan Depository Receipt listing. We believe we are poised for meaningful success in the quarters ahead."
IFA Europe ... any updates confirming NTEK on display?
It's a self-fulfilling prophecy ... if folks fear dilution and the share price drops accordingly, then you are absolutely right the dilution will be a toxic spiral.
BUT, if become more confident in the fundamentals and potential (such as in the article) then the share price could increase such that the dilution woudn't necessarily be toxic, but -- rather -- could be seen as healthy in getting the company to its goals..
I'm still trying to figure out this company and don't have a strong opinion but wanted to point out both sides of the argument.
You guys know I'm optimistic about the PLSB, especially Cabana, but I think having exclusive men's and womens' flavors for Pulse might have been a mis-step. Purchasing behavior is psychological (not 100% rational) and I think folks will feel their choices are being limited/dictated to them ... this might not sound like a big deal but such psychological factors can have a siginifcant influence especially when picking one drink from many as what for most would be a split-second decision.
I could be wrong, however, if perhaps studies have shown women tend to prefer certain flavors verus men ... nonetheless, not being able to try certain flavors (what guy is going to buy a woman's drink at a drugstore line) might still offset the benefit ... I'm not an expert here so perhaps this is something management has considered ...??
On a positive note, I think 'Cabana' is BRILLIANT marketing ... while drinking your lemonade evokes the idea of being on a beach/resort vacation. What better image than that!? Drug companies spend millions coming up with names so this is important.
PLSB - my case of Cabana Lemonades arrived ealier this week! Have to say they were exactly what I was hoping ... sweet but not nearly as sugary as most drinks, fruit flavor, only natural ingredients and only 60 calories for a big bottle.
Taste MUCH better than all the 0 calorie stuff out there!
Perhaps one issue is that they don't prominently label on the front as a low-calorie drink so I'm not sure if they've missed that marketing opportunity. On the other hand, some folks might be turned off in thinking that the flavor would be lacking so perhaps this was intentional.
Either way, as folks try it out I think Cabana will appeal to a very large niche!
PLSB - my case of Cabana Lemonades arrived ealier this week. Have to say they were exactly what I was hoping ... sweet but not nearly as sugary as most drinks, fruit flavor, only natural ingredients and only 60 calories for a big bottle.
Tastes much better than all the 0 calorie stuff out there!
They don't prominently label on the front as a low-calorie drink so I'm not sure if they've missed that marketing opportunity. On the other hand, some folks might be turned off in thinking that the flavor would be lacking so perhaps this was intentional.
Either way, I think Cabana will appeal to a very large niche.